Reveals a significant association of TMPO-AS1 with poor clinical outcomes in lung adenocarcinoma, suggesting its role as a molecular classifier.
The study concludes that TMPO-AS1 is overexpressed in cases of LUAD, highlighting its potential as a molecular classifier for LUAD and a prognostic biomarker associated with poor clinical outcomes.
No takes yet. Share an insight, caveat, or question.
Nirmal et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: